Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
Trial Parameters
Brief Summary
This study is a prospective single-center clinical study, which aims to observe and evaluate the efficacy and safety of apatinib combined with temozolomide and oral etoposide in the treatment of recurrent medulloblastoma in children.
Eligibility Criteria
Inclusion Criteria: 1. Age 2-21 (at the time of diagnosis), no gender limit. 2. After biopsy or surgery, the first postoperative pathological diagnosis is medulloblastoma. 3. The recurrence of the tumor is confirmed by MRI, that is, the diameter of the lesion on the enhanced MRI image is ≥1cm, and ≥2 slices (slice spacing 5mm) are visible; or after another biopsy or surgery, the pathological diagnosis is medulloblastoma. 4. The time interval from the last radiotherapy is ≥4 weeks. 5. The time interval from the last chemotherapy is ≥4 weeks, and the patients have fully recovered from the acute toxicity of the last treatment. If you receive nitrosourea chemotherapeutics before enrollment, the interval between enrollment and the last chemotherapy is ≥6 weeks. 6. The interval between the last biopsy or surgery is ≥2 weeks. 7. KPS score ≥50 (patient\> 12 years old), or Lansky score ≥ 50 (patient ≤ 12 years old). 8. If the patient is taking glucocorticoid therapy, the hormone dosage has stab